FAE Stock Overview
Researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Faes Farma, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.53 |
| 52 Week High | €3.83 |
| 52 Week Low | €3.06 |
| Beta | 0.47 |
| 1 Month Change | -5.37% |
| 3 Month Change | 2.17% |
| 1 Year Change | 10.68% |
| 3 Year Change | -2.89% |
| 5 Year Change | 2.32% |
| Change since IPO | 247.67% |
Recent News & Updates
Does Faes Farma (BME:FAE) Deserve A Spot On Your Watchlist?
Mar 01
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0332
Jan 06Faes Farma's (BME:FAE) Dividend Will Be €0.0332
Dec 03Recent updates
Does Faes Farma (BME:FAE) Deserve A Spot On Your Watchlist?
Mar 01Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0332
Jan 06Faes Farma's (BME:FAE) Dividend Will Be €0.0332
Dec 03Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316
Dec 18Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316
Dec 04Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?
Nov 24Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly
May 03Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?
Sep 21Is Faes Farma (BME:FAE) A Risky Investment?
Aug 03Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
Jun 17Is Faes Farma (BME:FAE) Using Too Much Debt?
Mar 27Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
Dec 13Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17
Nov 29Is Faes Farma (BME:FAE) A Risky Investment?
Sep 21Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Faes Farma (BME:FAE) Using Too Much Debt?
May 01Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)
Apr 07Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?
Mar 22Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations
Mar 06Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment
Feb 22I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease
Jan 16Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly
Dec 08Shareholder Returns
| FAE | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 7.0% | 1.2% | 1.8% |
| 1Y | 10.7% | -11.5% | 19.5% |
Return vs Industry: FAE exceeded the Spanish Pharmaceuticals industry which returned -11.5% over the past year.
Return vs Market: FAE underperformed the Spanish Market which returned 19.5% over the past year.
Price Volatility
| FAE volatility | |
|---|---|
| FAE Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in ES Market | 6.3% |
| 10% least volatile stocks in ES Market | 0.7% |
Stable Share Price: FAE has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: FAE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 1,762 | n/a | faesfarma.com |
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. It operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It offers products for various therapeutic areas.
Faes Farma, S.A. Fundamentals Summary
| FAE fundamental statistics | |
|---|---|
| Market cap | €1.10b |
| Earnings (TTM) | €111.36m |
| Revenue (TTM) | €510.04m |
9.9x
P/E Ratio2.2x
P/S RatioIs FAE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAE income statement (TTM) | |
|---|---|
| Revenue | €510.04m |
| Cost of Revenue | €167.11m |
| Gross Profit | €342.93m |
| Other Expenses | €231.57m |
| Earnings | €111.36m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 67.24% |
| Net Profit Margin | 21.83% |
| Debt/Equity Ratio | 6.9% |
How did FAE perform over the long term?
See historical performance and comparisonDividends
4.5%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 04:11 |
| End of Day Share Price | 2025/03/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Faes Farma, S.A. is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Álvaro Arístegui Echevarría | Ahorro Corporación |
| Kamla Singh | AlphaValue |
| Guilherme Sampaio | Banco BPI, S.A. |